UBS Downgrades Achillion Pharmaceuticals Following Johnson & Johnson Deal

Biotechnology company Achillion Pharmaceuticals (NASDAQ: ACHN) fell about 10% in trading on Wednesday, May 20 following the company’s announcement that it licensed its hepatitis C drug pipeline to Johnson & Johnson (NYSE: JNJ) for $1.1 billion.

In the terms of the deal, Johnson & Johnson will pay Achillion Pharmaceuticals milestone Payments Payments One of the bases of mediums of exchange in the modern world, a payment constitutes the transfer of a legal currency or equivalent from one party in exchange for goods or services to another entity. The payments industry has become a fixture of modern commerce, though the players involved and means of exchange have dramatically shifted over time.In particular, a party making a payment is referred to as a payer, with the payee reflecting the individual or entity receiving the payment. Most commonl One of the bases of mediums of exchange in the modern world, a payment constitutes the transfer of a legal currency or equivalent from one party in exchange for goods or services to another entity. The payments industry has become a fixture of modern commerce, though the players involved and means of exchange have dramatically shifted over time.In particular, a party making a payment is referred to as a payer, with the payee reflecting the individual or entity receiving the payment. Most commonl Read this Term totaling $1.1 billion throughout the development of its hepatitis C drug. Johnson & Johnson will also purchase 18.4 million new shares in Achillion Pharmaceuticals for $12.25 a share, totaling $224 million. Additionally, Johnson & Johnson will have exclusive rights to develop and commercialize the hepatitis C pipeline and will have to pay Achillion royalties on any future sales worldwide. The royalty percentages will range from the mid-teens to low-twenties.

Investors did not react too kindly to this news as they were expecting a distributor to buy Achillion’s hepatitis C drug pipeline outright.

Achillion CEO Milind Deshpande, Ph.D., said of the deal, “We believe that [Johnson & Johnson’s pharmaceutical R&D department] renowned expertise in HCV development and commercialization enables a synergistic opportunity to rapidly advance our combined HCV assets toward the market while simultaneously achieving an optimized treatment regimen for all HCV patients…Furthermore, we believe that their investment in Achillion through Johnson & Johnson Innovation - JJDC allows us to maximize the value from our HCV portfolio and also positions us to become a leader in complement factor D inhibition, applying our broad platform to a wide number of complement-related diseases. We believe this strategy provides an ideal scenario to create further value for our shareholders."

UBS analyst Andrew Peters weighed in on Achillion Pharmaceuticals on May 20, downgrading his rating from Buy to Neutral and cutting his price target from $19 to $11.50. The analyst attributed his downgrade to the limited potential upside the Achillion and Johnson & Johnson collaboration has for the stock.

Overall, Andrew Peters has a 58% success rate recommending stocks and a +20.7% average return per recommendation.

Similarly on May 20, JMP Securities analyst Liisa Bayko downgraded her rating on Achillion Pharmaceuticals from Outperform to Market Perform with a price target of $24. The analyst believes the deal’s platform “appears to have blockbuster potential” but prefers to hold out until the company starts to benefit from outsourcing its hepatitis C virus pipeline.

Liisa Bayko has an overall success rate of 73% recommending stocks and a +55.2% average return per recommendation.

On average, the top analyst consensus for Achillion Pharmaceuticals is Hold.